CN112457297A - PARP protein degradation agent and preparation method and application thereof - Google Patents
PARP protein degradation agent and preparation method and application thereof Download PDFInfo
- Publication number
- CN112457297A CN112457297A CN202011328048.7A CN202011328048A CN112457297A CN 112457297 A CN112457297 A CN 112457297A CN 202011328048 A CN202011328048 A CN 202011328048A CN 112457297 A CN112457297 A CN 112457297A
- Authority
- CN
- China
- Prior art keywords
- parp
- parp protein
- compound
- formula
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A PARP protein degradation agent as shown in X-Y-Z or X-Z, its preparation method and application are provided: X-Y-Z (I-1) or X-Z (I-2), X represents a ligand of PARP protein, Z represents a ligand of E3 ligase, Y represents a chain connecting X and Z, and the compound can target and degrade PARP protein and can be further used for treating or preventing tumors.
Description
Technical Field
The invention relates to the field of preparation of antitumor drugs, and particularly relates to a compound for targeted degradation of PARP protein, and a preparation method and application thereof.
Background
Poly (ADP-ribose) polymerase, PARP, is a ribozyme that is closely related to DNA repair, particularly to BER repair of single strand damage of DNA, and includes 18 subtypes, of which PARP-1 is the highest in eukaryotic cells. When tumor cell DNA is damaged by chemotherapeutics or ionizing radiation and the like, PARP-1 is quickly activated, NAD + is used as a substrate, poly (adenosine diphosphate) ribosyl (ADP) is transferred to a specific protein, and the PARP-1 catalyzes the nuclear saccharification (PAR) of the poly (adenosine diphosphate) of the specific protein to start a DNA repair process. Studies have shown that PARP-1 is involved in DNA repair pathways such as BER, HR, and NHEJ.
The PARP inhibitor can inhibit PAR function of PAPR to ensure that damaged DNA cannot be timely and effectively repaired, or the PARP inhibitor is combined with NAD + combination pocket of PARP1 (or PARP2) to cause conformational isomerism, so that PARP is captured at damaged DNA and cannot be subsequently repaired, and both of the PARP inhibitor and the PARP inhibitor can kill tumor cells. Although the PARP inhibitor has achieved surprising results in clinic, the content of PARP protein cannot be affected by the conventional PARP small molecule inhibitor, and the PARP protein can rapidly recover the activity after drug withdrawal; the phenomenon of drug resistance is easy to appear. Even after the medicine is stopped, the tumor cells need a certain time to recover the content of the nuclear PARP protein, so that the PARP protein degrading agent based on the PROTAC technology can effectively and durably inhibit the growth of the tumor.
Currently, several PARP1/2 degradants have been reported, including compound 1Zhao, q.; lan, t.; su, s.; rao, Y.Industtion of apoptosis in MDA-MB-231Breast cancer cells by a PARP1-targeting PROTAC small molecule. chem.Comm.2019,55,369-372 Compound 2(iRucaparib-AP5), 3(iRucaparib-AP6), and 4(iVeliparib AP6) Wang, S.; han, L.; han, J.; li, P.; ding, q.; zhang, q. -j.; liu, z. -p.; chen, c.; yu, Y.Ungroupling of PARP1 mapping and inhibition using selective PARP1 degradation. Nat.Chem.biol.2019,15, 1223-; yang, j.; chen, y. -w.; discovery of SK-575as a high hly post and efficiency proteins Targeting kernel (PROTAC) digrader of PARP1 for Targeting cancer.J.Med.chem 2020.DOI: 10.1021/acs.jmedchem.0c00821.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention provides a PARP protein degradation agent and a preparation method and application thereof, the compound adopts a double-target-point molecular structure, and target protein is degraded in a targeted way by using a PROTAC (protein-targeting chimeras) technology, namely, an ubiquitination degradation system which is responsible for removing defective proteins in cells. One end of the molecule is targeted and combined with E3 ligase MDM2, the other end of the molecule is targeted and combined with PARP protein, the structures at the two ends are connected through a chain (linker) to form a complete compound molecule, and the compound is used for ubiquitinating a target protein through E3 ligase and guiding the target protein to enter a proteasome degradation system to specifically degrade the target protein.
Compared with a PARP inhibitor, the nilapanib provided by the invention can play a role in proliferation inhibition in breast cancer cells such as MDA-MB-231 at a lower concentration. Therefore, the compound has potential application value in the anti-tumor field.
In particular, a PARP protein degradation agent represented by formula I-1 or I-2:
X-Y-Z (I-1) or X-Z (I-2)
Wherein X represents a ligand for PARP protein, Z represents a ligand for E3 ligase, and Y represents a chain linking X and Z;
the X is a formula II-1, the Z is a compound shown as a formula II-2,
the Y is a compound shown as a formula III-1,
each n is independently an integer of 1 to 10
In detail, the PARP protein degradation agent is:
formula 1-1, structure X-Z type
Formula 1-2, n ═ 1
Formula 1-3, n ═ 2
Formula 1-4, n ═ 3
Formula 1-5, n ═ 4
Formula 1-6, n ═ 5
The preparation process of the compound comprises the following steps:
drawings
FIG. 1 is a schematic diagram of the degradation of PARP protein of different tumor cell lines by the PARP protein degrading agent shown in example 4 of the present invention, and it can be seen that the compound NN3 shown in formulas 1-4 significantly degrades MDA-MB-231 and MCF-7PARP proteins.
Detailed Description
The following examples of the present invention are described in further detail, and are intended to be illustrative, but not limiting, of the present invention.
EXAMPLE 1 preparation of Compound represented by formula 1-1
Formula 1-1
Mixture of Nutlin acid intermediate (123.31mg,0.25mmol), HATU (70mg,0.184mmol) and DIEA (90. mu.L) dried DMF (3.78mL) was stirred at room temperature in a round bottom flask for 0.5 h. Then, a solution of nilapanib (79mg,0.25mmol) in 0.5mL anhydrous DMF was added slowly. The reaction mixture was stirred at room temperature for 12 hours. The water and mixture were washed once with saturated aqueous NaCl solution by quenching the reaction and the ethyl acetate was extracted with diethyl ether. The organic layer was washed with anhydrous Na2SO4 was dried and evaporated in vacuo to give the crude product, which was further purified by chromatography on silica gel (DCM: MeOH ═ 40: 1) to give the product.
1H NMR(400MHz,Chloroform-d)δ9.18–8.96(m,1H),8.54(d,J=5.4Hz,1H),8.32(dd,J=6.7,3.6Hz,1H),7.99–7.75(m,3H),7.61(dd,J=8.4,3.4Hz,1H),7.41(t,J=7.6Hz,2H),7.30(d,J=4.3Hz,1H),7.27(d,J=7.4Hz,1H),7.15–7.01(m,4H),7.00–6.81(m,4H),6.71–6.44(m,2H),6.20(dd,J=10.8,3.3Hz,1H),5.67–5.18(m,2H),4.65(t,J=13.0Hz,2H),4.25(dd,J=37.8,15.8Hz,1H),4.11(s,1H),3.96(d,J=15.9Hz,1H),3.92–3.68(m,6H),3.47(s,2H),3.27–3.06(m,3H),3.05–2.72(m,2H),2.65(t,J=12.1Hz,1H),2.14(d,J=10.6Hz,1H),1.83–1.57(m,2H),1.46–1.33(m,6H).[M-H]939.80。
EXAMPLE 2 preparation of the Compound represented by the formula 1-2
Formula 1-2
Mixture of Nutlin acid intermediate (123.31mg,0.25mmol), HATU (70mg,0.184mmol) and DIEA (90. mu.L) dried DMF (3.78mL) was stirred at room temperature in a round bottom flask for 0.5 h. Then, NH is added2-PEG1A solution of-COOtBu (33.26mg,0.25mmol) in 0.5mL anhydrous DMF was slow. The reaction mixture was stirred at room temperature for 12 hours. The water and mixture were washed once with saturated aqueous NaCl solution by quenching the reaction and the ethyl acetate was extracted with diethyl ether. The organic layer was washed with anhydrous Na2SO4 was dried and evaporated in vacuo to give the crude product, which was further purified by chromatography on silica gel (DCM: MeOH ═ 40: 1) to give the product.
To a solution of the Nutlin derivative ester (140mg, 0.020mmol) in DCM (1mL) was added TFA (2mL) at 0 ℃. After stirring at room temperature for 17 hours, the resulting mixture was diluted with toluene (10mL) and evaporated. The residue was purified by flash column chromatography (initially 3:99 methanol-dichloromethane, fractionated to 1: 9 methanol-dichloromethane) to give 123mg of Nutlin derivative acid intermediate.
Mixture of Nutlin derivative acid intermediate (123.31mg,0.25mmol), HATU (70mg,0.184mmol) and DIEA (90. mu.L) dried DMF (3.78mL) was stirred at room temperature in a round bottom flask for 0.5 h. Then, a solution of nilapanib (79mg,0.25mmol) in 0.5mL anhydrous DMF was added slowly. The reaction mixture was stirred at room temperature for 12 hours. The water and mixture were washed once with saturated aqueous NaCl solution by quenching the reaction and the ethyl acetate was extracted with diethyl ether. The organic layer was dried over anhydrous Na 2SO 4 and evaporated in vacuo to give the crude product, which was further purified by chromatography on silica gel (DCM: MeOH ═ 40: 1) to give the product.
1H NMR(400MHz,Chloroform-d)δ9.05(s,1H),8.54(d,J=3.6Hz,1H),8.32(d,J=7.0Hz,1H),8.03–7.74(m,3H),7.59(t,J=8.6Hz,1H),7.41(dd,J=8.3,6.0Hz,3H),7.26(s,1H),7.16–6.79(m,8H),6.68–6.35(m,2H),6.20(s,1H),5.69–5.41(m,2H),5.31(s,1H),4.83–4.48(m,2H),4.01–3.70(m,9H),3.62–3.40(m,7H),3.13(s,3H),2.84–2.61(m,3H),2.14(d,J=12.3Hz,1H),1.86–1.54(m,3H),1.44–1.29(m,6H).[M+H]1056.50。
Example 3 the compounds represented by formulas 1 to 3 were prepared according to the above preparation method.
1H NMR(400MHz,Chloroform-d)δ9.07(s,1H),8.56(s,1H),8.33(d,J=7.1Hz,1H),8.04(s,1H),7.88(dq,J=25.5,9.0,8.1Hz,3H),7.61(d,J=8.5Hz,1H),7.41(dd,J=19.7,8.8Hz,2H),7.15–6.78(m,8H),6.56(d,J=8.0Hz,1H),6.49(s,1H),6.07(s,1H),5.59(d,J=9.5Hz,1H),5.49(d,J=9.4Hz,1H),4.85–4.67(m,1H),4.66–4.53(m,1H),4.13(d,J=7.5Hz,1H),3.99(q,J=14.5,12.8Hz,2H),3.86(d,J=8.0Hz,6H),3.74(d,J=14.1Hz,1H),3.64(dd,J=12.2,5.1Hz,4H),3.58–3.38(m,5H),3.30(s,1H),3.13(d,J=10.6Hz,3H),2.98(s,1H),2.91(s,1H),2.67(dd,J=21.5,9.3Hz,4H),2.25–1.99(m,2H),1.37(d,J=16.6Hz,6H).[M+H]1100。
Example 4 Compounds represented by formulas 1 to 4 were prepared according to the above preparation method.
Formulas 1-4(NN3)
1H NMR(400MHz,Chloroform-d)δ9.07(s,1H),8.55(s,1H),8.37–8.21(m,1H),7.96–7.74(m,3H),7.58(d,J=8.4Hz,1H),7.41(d,J=7.7Hz,3H),7.26(d,J=7.6Hz,2H),7.08(d,J=7.5Hz,2H),7.03(d,J=7.5Hz,2H),6.93(d,J=7.8Hz,2H),6.88(d,J=7.7Hz,2H),6.54(d,J=8.4Hz,1H),6.48(s,1H),6.31(d,J=18.1Hz,1H),5.57(d,J=9.6Hz,1H),5.48(d,J=9.6Hz,1H),4.78–4.52(m,2H),4.04–3.89(m,2H),3.85(s,5H),3.81(d,J=4.4Hz,2H),3.73–3.55(m,10H),3.52(s,3H),3.41(s,2H),3.27(s,2H),2.98–2.86(m,1H),2.80(d,J=12.1Hz,1H),2.72–2.58(m,3H),1.85–1.56(m,4H),1.35(dd,J=13.8,4.4Hz,6H).[M+Na]1166.60。
Example 5 Compounds represented by formulae 1 to 5 were prepared according to the above preparation method.
1H NMR(400MHz,Chloroform-d)δ9.11(s,2H),8.55(d,J=4.6Hz,2H),8.33(dd,J=8.3,2.1Hz,2H),8.20–8.00(m,2H),7.99–7.75(m,6H),7.67–7.49(m,1H),7.49–7.33(m,5H),7.18–6.99(m,1H),6.90(d,J=8.4Hz,1H),6.63–6.41(m,1H),6.21(d,J=7.9Hz,3H),5.84–5.07(m,2H),4.91–4.43(m,3H),4.26–
3.55(m,6H),3.48–3.05(m,5H),3.05–2.44(m,6H),2.42–2.04(m,8H),1.30(d,J=18.5Hz,9H),1.03–0.68(m,6H).[M+Na]1212.40。
Example 6 Compounds represented by formulae 1 to 6 were prepared according to the above preparation method.
1H NMR(400MHz,Chloroform-d)δ9.07(d,J=2.9Hz,1H),8.61(s,1H),8.31(d,J=6.4Hz,1H),8.17(s,1H),8.05(d,J=8.7Hz,3H),7.98(d,J=8.7Hz,2H),7.93(d,J=8.3Hz,1H),7.60(d,J=8.5Hz,1H),7.30(s,1H),7.27(s,1H),7.09(d,J=8.4Hz,4H),7.03(d,J=8.5Hz,3H),6.94(d,J=8.4Hz,2H),6.89(d,J=8.3Hz,2H),6.64(s,2H),6.48(d,J=2.2Hz,1H),6.31(d,J=2.9Hz,1H),5.58(d,J=9.7Hz,1H),5.49(d,J=9.7Hz,1H),4.62(dt,J=9.9,5.5Hz,3H),4.00–3.92(m,4H),3.85(s,5H),3.77(d,J=15.6Hz,1H),3.71–3.64(m,6H),3.63(s,5H),3.60–3.54(m,5H),3.54–3.44(m,5H),3.39(q,J=5.1Hz,3H),3.28(dt,J=13.3,5.9Hz,2H),3.12(p,J=7.1,6.2Hz,2H),1.40–1.34(m,6H).[M+H]1234.55。
Example 4 the compounds of the present invention have a strong PARP degrading activity, and the following tests were conducted by taking the small molecule compounds represented by formulas 1-1 to 1-6 as examples.
1. Preparing a main solution:
configuration of test compounds and positive control drugs nilapani and Nutlin: an appropriate amount of test compound powder was weighed, dissolved in DMSO to give a final concentration of 10mmol/L, stored at-20 ℃ in a dark place, thawed immediately, and diluted to the desired concentration.
RPMI1640 culture solution: each bag of RPMI1640 powder is dissolved in about 800ml of double distilled water, 1.5g of NaHCO3, 2.5g of glucose and 0.11g of sodium pyruvate are added, and the solution is fully dissolved and supplemented to 1000ml by the double distilled water. Filtering with 0.22 μm microporous membrane for sterilization, packaging, and storing at 4 deg.C. Before use, 10% fetal bovine serum, 1 × double antibody was added.
DMEM culture solution: each bag of DMEM powder is dissolved in about 800ml of double distilled water, and 1.5g of NaHCO3, 2.5g of glucose and 0.11g of sodium pyruvate are added and fully dissolved, and the solution is supplemented to 1000ml with double distilled water. Filtering with 0.22 μm microporous membrane for sterilization, packaging, and storing at 4 deg.C. Before use, 10% fetal bovine serum, 1 × double antibody was added.
PBS buffer (pH 7.4): weighing 8.0g of NaCl, 0.2g of KCl and Na2HPO4·12H2O 1.44g,KH2PO4·12H2Dissolving O0.24 g in 900ml double distilled water, adjusting pH to 7.4 with HCl, diluting to 1000ml with double distilled water, autoclaving, and storing at room temperature.
2. Immunoblot analysis for detecting protein expression level of cells
(1) Electrophoresis: the denatured protein samples were loaded in equal amounts onto 5% concentrated gel and 10% separation gel (mainly composed of ddH2O, 30% polyacrylamide, 1.5M Tris-HCl (pH8.8) or 1.0M Tris-HCl (pH6.8), 10% SDS, 10% ammonium persulfate, TEMED), with a loading of about 40. mu.g per well of protein, run at 100V at constant pressure, and stop the electrophoresis when bromophenol blue runs to the bottom of the gel.
(2) Film transfer: after electrophoresis is finished, the glass plate is disassembled, the gel is taken out, the concentrated gel is cut off, the separation gel is properly sheared according to the molecular weight of the target protein and then is soaked in the precooled membrane transferring liquid so as to avoid drying, and meanwhile, the filter paper and the sponge are also soaked in the precooled membrane transferring liquid. Cutting a PVDF membrane with the size similar to that of the gel, soaking in methanol for 2min to activate the membrane, and then making a sandwich according to the following arrangement sequence: and sequentially stacking 1 spongy cushion, 2 pieces of filter paper, gel, a PVDF (polyvinylidene fluoride) membrane, 2 pieces of filter paper and one spongy cushion on the negative electrode. Note that: the PVDF membrane must be allowed to drive off the bubbles after application to the gel. And then, installing an electrophoresis tank in the correct positive and negative electrode directions for wet rotation, putting ice blocks around the electrophoresis tank for cooling, and adjusting the voltage to be constant current 200V (1.5 h).
(3) And (3) sealing: and after the membrane transfer is finished, the PVDF membrane is washed for 5min in TBST, and then is put into 5 percent of confining liquid to be confined on a decoloring shaking table for 0.5-1 h.
(4) Antibody incubation: diluting the primary antibody blocking solution or the primary antibody dilution solution according to a ratio of 1:500-1:1000, covering the diluted primary antibody blocking solution or the diluted primary antibody dilution solution on a PVDF membrane, incubating for 2h or overnight at 4 ℃ at room temperature, and then washing for 5min with TBST for three times. After diluting the secondary antibody according to the ratio of 1:5000, incubating the secondary antibody with a PVDF membrane for 1h at room temperature on a shaking table, and then washing the secondary antibody with TBST for three times, 5min each time.
(5) Chemiluminescence, development, fixation: and mixing the reagent A and the reagent B in equal volume, dripping the mixture on an ImageStation 4000MM imager, covering the ECL reagent with the PVDF membrane with the front surface facing downwards, and exposing according to the operation instruction of the imager to obtain a protein band result.
3. As a result: the PARP protein degradation activity of the PARP protein degradation agent of the invention is as follows, after the cell lines MDA-MB-231 and MCF-7 are treated for 48 hours by the compound NN3 obtained in example 4, the result of Western blot analysis can obviously observe the degradation effect of the compound NN3 on the PARP protein under different dosages. The degradation of PARP protein by compound NN3 at 12.5uM, 25uM in the MDA-MB-231 cell line is shown.
Example 5 half-maximal inhibition of tumor cell lines of different origins
Different tumor cell lines: human breast cancer cell lines were selected: MCF-7, HCC1937, MDA-MB-231, SKBR3, MX-1 normal mammary cells MCF-10A, so as to examine the half inhibition rate activity of the compound NN3 on tumor cell lines of different sources. The corresponding cells were cultured in RPMI1640 medium containing 10% fetal bovine serum, 100IU/ml penicillin and 100. mu.g/ml streptomycin. The cells were cultured in an incubator at 37 ℃ and saturated humidity with 5% CO2, and cells in the logarithmic growth phase were used for the experiment. Cells in logarithmic growth phase were seeded at 4X 104 cells/ml in 96-well plates at 180. mu.l per well.
The experimental groups were each added 20. mu.l of the compound prepared in examples 1-6 at an initial concentration of 200uM and diluted in half, the negative control group was not dosed, and the positive control agents Nilaparib and Nutlin-3a (purchased from Shanghai Bopont) were each provided with 3 parallel wells and incubated at 37 ℃ for 48 h. 20. mu.l/well of 5mg/ml MTT solution was added, and after further culturing for 4 hours, the supernatant was removed, 150. mu.l DMSO was added, shaking was carried out on a micro-shaker for 10 minutes, and the absorbance (OD value) was measured at a wavelength of 570nm with a microplate reader. The cell growth inhibition rate [ cell growth inhibition rate (control OD-experimental OD)/control OD × 100% ]wascalculated from the absorbance, and IC50 values were calculated by the Logit method, and the experiment was repeated 3 times to obtain an average value.
Example 4 of the present invention shows different biological activities for different breast cancer cell lines. Compared with the positive control drug Nilaparib, Nutlin-3a, the compound NN3 shows stronger antitumor effect, but has no cytotoxicity to normal mammary cells MCF-10A.
TABLE 1 PARP degrader cellular level bioactivity assay (48h maximum inhibition of Compound 200uM or IC50 (uM); NS: not tested)
Compound (I) | Name of | Molecular weight | MDA-MB-231 | MX-1 | MCF-7 | SKBR3 | HCC1937 | MCF-10A |
1-1 | NN0 | 1011 | 5.59% | 34.97% | 10.19% | 18.63% | Has no inhibiting effect | NS |
1-2 | NN1 | 1055 | Has no inhibiting effect | Has no inhibiting effect | Has no inhibiting effect | 11.39% | Has no inhibiting effect | NS |
1-3 | NN2 | 1099.41 | 99.03uM | 16.71% | 42.401uM | 40.14% | 40.06% | NS |
1-4 | NN3 | 1143 | 22.15uM | 24.6% | 20.88uM | 45.33% | 47.02% | 38.21% |
1-5 | NN4 | 1187 | 161.52uM | 80.26uM | 54.32uM | 199.11uM | 29.63% | NS |
1-6 | NN5 | 1231 | 159uM | 59.50uM | 117.93uM | 266.47uM | 243.45uM | NS |
Nilaparib | 320 | 70.40uM | 49.91uM | 38.69uM | 70.23uM | 97.15uM | 87.16uM | |
Nutlin | 581.49 | 64.04uM | 50.45uM | 42.66uM | 75.61uM | 66.44uM | 63.82uM |
Claims (6)
1. A PARP protein degrading agent represented by formula I-1 or I-2:
X-Y-Z (I-1) or X-Z (I-2)
Wherein X represents a ligand of PARP protein, Z represents a ligand of E3 ligase, and Y represents a chain connecting X and Z.
5. use of the PARP protein degrading agent of claim 1 for the preparation of a medicament for the treatment or prevention of tumors.
6. The use according to claim 5, wherein the neoplasm is breast cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011328048.7A CN112457297B (en) | 2020-11-24 | 2020-11-24 | PARP protein degradation agent and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011328048.7A CN112457297B (en) | 2020-11-24 | 2020-11-24 | PARP protein degradation agent and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112457297A true CN112457297A (en) | 2021-03-09 |
CN112457297B CN112457297B (en) | 2023-04-28 |
Family
ID=74799705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011328048.7A Active CN112457297B (en) | 2020-11-24 | 2020-11-24 | PARP protein degradation agent and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112457297B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116640123A (en) * | 2022-02-15 | 2023-08-25 | 沈阳药科大学 | Bifunctional molecule compound for inducing degradation of HK2 protein and synthesis and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108379591A (en) * | 2018-04-03 | 2018-08-10 | 深圳大学 | The synthesis and its application of immune agonist target compound |
CN110357889A (en) * | 2018-04-09 | 2019-10-22 | 上海科技大学 | Protein degradation target compound, its antitumor application thereof, wherein mesosome and intermediate application |
CN111514309A (en) * | 2019-02-03 | 2020-08-11 | 重庆阿普格雷生物科技有限公司 | Polyethylene glycol coupled drug, preparation method and application thereof |
CN111741769A (en) * | 2018-04-20 | 2020-10-02 | 四川科伦博泰生物医药股份有限公司 | Multifunctional compound, preparation method and medical application thereof |
CN112300074A (en) * | 2019-08-02 | 2021-02-02 | 北京盈科瑞创新药物研究有限公司 | Indazole formamide compound and preparation method and application thereof |
-
2020
- 2020-11-24 CN CN202011328048.7A patent/CN112457297B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108379591A (en) * | 2018-04-03 | 2018-08-10 | 深圳大学 | The synthesis and its application of immune agonist target compound |
CN110357889A (en) * | 2018-04-09 | 2019-10-22 | 上海科技大学 | Protein degradation target compound, its antitumor application thereof, wherein mesosome and intermediate application |
CN111741769A (en) * | 2018-04-20 | 2020-10-02 | 四川科伦博泰生物医药股份有限公司 | Multifunctional compound, preparation method and medical application thereof |
CN111514309A (en) * | 2019-02-03 | 2020-08-11 | 重庆阿普格雷生物科技有限公司 | Polyethylene glycol coupled drug, preparation method and application thereof |
CN112300074A (en) * | 2019-08-02 | 2021-02-02 | 北京盈科瑞创新药物研究有限公司 | Indazole formamide compound and preparation method and application thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116640123A (en) * | 2022-02-15 | 2023-08-25 | 沈阳药科大学 | Bifunctional molecule compound for inducing degradation of HK2 protein and synthesis and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112457297B (en) | 2023-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brai et al. | Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents | |
Pucci et al. | Improving the bioactivity of Zn (II)-curcumin based complexes | |
Simeone et al. | Design, Synthesis and Characterisation of Guanosine‐Based Amphiphiles | |
Ottria et al. | Synthesis and evaluation of in vitro anticancer activity of some novel isopentenyladenosine derivatives | |
Rakesh et al. | Xanthone conjugated amino acids as potential anticancer and DNA binding agents: Molecular docking, cytotoxicity and sar studies | |
CN112457297A (en) | PARP protein degradation agent and preparation method and application thereof | |
Banaspati et al. | Photocytotoxic copper (II) complexes of N-salicylyl-L-tryptophan and phenanthroline bases | |
CN101239979A (en) | Heterocyclic compound capable of inversing tumor cell drug tolerance, preparation method and application thereof | |
Zhang et al. | Investigation of the electrochemical interaction behavior of DNA with 5-fluorouracil derivatives | |
CN112500293B (en) | 1,1' -biphenyl-2, 6-diphenol compound and application thereof | |
CN102617676B (en) | Zidovudine quinoline conjugated compound, preparation method thereof and application for liver cancer resistance | |
FI87357B (en) | FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA 3 ', 4'-DIKVAEVESUBSTITUERADE GLUKOSIDDERIVAT AV EPIPODOFYLLOTOXIN. | |
CN107266407B (en) | Photosensitive targeted anti-tumor prodrug capable of killing tumor cells in response to nitroreductase and preparation method and application thereof | |
CN115894407A (en) | CIT fluorophore of 1-furan and thienyl-2-alkenyl-1-ketone containing nitrogen mustard and preparation method and application thereof | |
CN112430229B (en) | Compound for targeted degradation of PARP protein and preparation method and application thereof | |
CN115260053A (en) | Compound with antitumor activity and preparation method and application thereof | |
Zong et al. | A “D-π-A” type NiIIporphyrin-BODIPY hybrid: Expansion of visible-light absorption and antitumor activity of lymphoma cells | |
Lewis et al. | Pyrazolo [4, 3-d] pyrimidine nucleosides. 9. Studies on the isomeric N-methylformycins | |
CN106518941B (en) | Glycosyl beta-elemene derivatives and its preparation method and application | |
EP3650451A1 (en) | Compounds and their uses as fluorescent probes | |
CN102106831B (en) | Decitabine lyophilized preparation and preparation method thereof | |
EP4140504A1 (en) | Micelle comprising benzimidazole-carbohydrate conjugate compound, preparation method thereof and use thereof as anticancer agent or antiviral agent comprising the same | |
TWI777479B (en) | A use of cytisine derivatives | |
CN116836142B (en) | 3-chromone-2-sulfonyl acrylonitrile derivative and preparation method and application thereof | |
CN114181238B (en) | 7-ethyl-10-hydroxycamptothecine prodrug with fluorescence activity and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |